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RHBDF2 Mutations Are Associated with Tylosis,
a Familial Esophageal Cancer Syndrome
Diana C. Blaydon,1,14 Sarah L. Etheridge,1,14 Janet M. Risk,2 Hans-Christian Hennies,3 Laura J. Gay,1
Rebecca Carroll,4 Vincent Plagnol,5 Fiona E. McRonald,2 Howard P. Stevens,6 Nigel K. Spurr,7
D. Timothy Bishop,8 Anthony Ellis,9 Janusz Jankowski,1,12,13 John K. Field,10 Irene M. Leigh,11
Andrew P. South,11,15 and David P. Kelsell1,15,*
Tylosis esophageal cancer (TOC) is an autosomal-dominant syndrome characterized by palmoplantar keratoderma, oral precursor
lesions, and a high lifetime risk of esophageal cancer. We have previously localized the TOC locus to a small genomic interval within
chromosomal region 17q25. Using a targeted capture array and next-generation sequencing, we have now identifiedmissensemutations
(c.557T>C [p.Ile186Thr] and c.566C>T [p.Pro189Leu] in RHBDF2, which encodes the inactive rhomboid protease RHBDF2 (also known
as iRhom2), as the underlying cause of TOC.We show that the distribution of RHBDF2 in tylotic skin is altered in comparison with that
in normal skin, and immortalized tylotic keratinocytes have decreased levels of total epidermal growth factor receptor (EGFR) and
display an increased proliferative andmigratory potential relative to normal cells, evenwhennormal cells are stimulatedwith exogenous
epidermal growth factor. It would thus appear that EGFR signaling is dysregulated in tylotic cells. Furthermore, we also show an altered
localization of RHBDF2 in both tylotic and sporadic squamous esophageal tumors. The elucidation of a role of RHBDF2 in growth-factor
signaling in esophageal cancer will help to determine whether targeting this pathway in chemotherapy for this and other squamous cell
carcinomas will be effective.Esophageal cancer (predominantly squamous esophageal
cancer) is the sixth leading cause of cancer-related deaths
worldwide.1 Pathogenesis of esophageal squamous carci-
noma is still poorly understood, and there are few targeted
drugs to effectively treat the condition. Type A tylosis
(focal nonepidermolytic palmoplantar keratoderma; Fig-
ure 1A) is associated with a high risk of squamous cell
esophageal cancer (up to 95% by age 65) in three extensive
pedigrees (an example of the UK pedigree is shown in
Figure S1, available online).2–4 The incidence of other
cancers in these families is not altered.2,4 Tylosis esopha-
geal cancer (TOC [OMIM 148500])5 is inherited as an auto-
somal-dominant trait, and the cutaneous phenotype is
fully penetrant by the onset of puberty. Oral leukokeratosis
(Figure 1B) and follicular hyperkeratosis are also features of
the syndrome.6We have previouslymapped the TOC locus
to a small section of chromosomal region 17q25 by using
linkage and haplotype analysis in three extensive pedi-
grees from the UK, the USA, and Germany.7–10
With the development of high-throughput sequencing
platforms, we have revisited the TOC locus. This included
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the recombination and affected status of a family member.
The study was approved by National Health Services
research ethics committees, and all patients enrolled gave
their informed consent. Coordinates for all the exons
from this revised minimal region, chr17q25.1–q25.2
(Figure S2), as well as some noncoding sequence, were ex-
tracted from the UCSC Genome Browser database, and
probes were designed and included on a custom capture
microarray (Roche NimbleGen, Madison, WI, USA). DNA
from an affected individual from the UK family was
randomly fragmented with a Bioruptor sonicator (Diage-
node, Denville, NJ, USA), and the library of adaptor-ligated
DNA fragments was prepared according to the Illumina
protocol. The DNA library was then hybridized to the
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Figure 1. Mutations in RHBDF2 Underlie Tylosis
Clinical images of a tylosis patient showing the focal nonepidermolytic palmoplantar keratoderma (A) and oral leukokeratosis (B).
Sanger sequence traces (C) displaying the c.557T>C mutation identified in the UK and USA families and the c.566C>T mutation iden-
tified in the German family.
(D) Schematic illustrating of the structure of RHBDF2, a seven-transmembrane-domain protein, and the approximate location of the
alterations identified in tylosis patients. Protein alignment with ClustalW illustrates that the amino acid residues mutated in the tylosis
patients (in p.Ile186Thr and p.Pro189Leu) are highly conserved across a wide range of eukaryotic species as well as in RHBDF1, a closely
related member of the iRhom family.Raw 76 bp paired-end reads were aligned to the UCSC
human genome reference sequence hg18 with novoalign,
including the soft clipping, adaptor-trimming, and base-
call quality calibration options. We filtered clonal reads,
generated pileup, and called SNPs on the basis of allele
counts and read depth by using custom Perl/Cþþ scripts.
Exclusion of previously reported SNPs (by accessing dbSNPThe Americaand 1000 Genomes Browser via the Seattle SNP website)
revealed a novel isoleucine-to-threonine substitution
(c.557T>C [p.Ile186Thr]) in exon 6 of the RHBDF2
(NM_024599.5 [UCSC hg19 assembly]; Figure 1C). Using
a pyrosequencing assay to screen other members of the
UK and US families, we found that this mutation segre-
gated with the disease in both extensive tylosis-affectedn Journal of Human Genetics 90, 340–346, February 10, 2012 341
families. In brief, PCR primers and a pyrosequencing
primer were designed (Table S1) to cover the c.557T>C
mutation site. Hot-start PCR was carried out with
50 ng/ml of DNA template in each reaction (PCR condi-
tions: 94C for 5 min; 35 cycles of 94C for 30 s, 65C for
40 s, and 72C for 30 s; and a final extension of 72C for
10 min). Confirmation of PCR product quality and
freedom from contamination was established on 2%
agarose gels with ethidium bromide staining. Pyrose-
quencing was carried out with the PSQ 96MA System
(Biotage), including Single-Stranded Binding Protein
(PyroGold reagents), according to the manufacturers’
protocol. The c.557T>C mutation was heterozygous in
all affected family members genotyped (n¼ 34) and absent
in 16 unaffected family members. Previously, haplotype
data showed the segregation of two distinct disease haplo-
types between these two families;6 thus, the c.557T>C
mutations are likely to have arisen independently in the
two families. Standard PCR and Sanger sequence analysis
of the German tylosis-affected family revealed that
RHBDF2 contained a distinct missense substitution,
c.566C>T (p.Pro189Leu), which was 3 amino acids down-
stream of the c.557T>C mutation and segregated with the
disease in this family (Figure 1C). Analysis revealed that
both amino acids are highly conserved within the iRhom
(inactive rhomboid) family in the N-terminal portion of
the protein (Figure 1D). These mutations are not present
in dbSNP or the 1000 Genomes database. These data
strongly support RHBDF2 as the TOC-associated gene.
RHBDF2 (also known as RHBDL6 or iRhom2) belongs
to a family of seven transmembrane-spanning proteins
called rhomboids, which were first identified in Drosophila
and were shown to be serine intramembrane proteases
linked with epidermal growth factor receptor (EGFR)
signaling and mitochondrial remodeling.11–14 Rhomboid
proteins are relatively poorly understood proteases that
are involved in the preparation of proteins, including
epidermal growth factor (EGF), for export. Whereas
RHBDF2 is an iRhom lacking the necessary serine721
residue for protease activity, iRhoms have been shown to
regulate rhomboid-dependent proteolysis (and thus EGF
signaling) by targeting specific client proteins like EGF
for proteosomal removal by ER-associated degradation
(ERAD).15 There is little published data on RHBDF2,
although in vitro studies have shown that a closely related
family member, RHBDF1, can regulate epithelial cancer
cell growth and survival, possibly via GPCR-mediated
EGFR signaling and/or by interacting with TGFa
ligands.16,17
We performed immunohistochemistry to compare the
localization of RHBDF2 between control and tylotic skin
sections. We air dried frozen skin sections for 30–60 min
before staining, and we fixed sections by applying ice-
cold methanol-acetone (50:50) and left them to air dry
for 20 min. Sections were then permeabilized for 10 min
in 0.1% Triton X-100 and blocked for 20 min in 3% bovine
serum albumin (BSA). Rabbit-anti-RHBDF2 (Sigma,342 The American Journal of Human Genetics 90, 340–346, FebruaryHPA018080) was diluted 1:100 in 3% BSA and incubated
overnight at 4C. The following day, sections were washed
in PBS, incubated for 1 hr at room temperature with Alex-
afluor-488 goat-anti-rabbit secondary antibody, and
diluted 1:800 in PBS. Sections were counterstained with
100 ng/ml 40,6-diamidino-2-phenylindole (DAPI) and
mounted with Shandon Immu-Mount mounting medium
(Thermo Fisher Scientific, Waltham, MA, USA). Images
were taken with the Zeiss Meta-510 LSM confocal micro-
scope. In control skin, RHBDF2 appeared throughout the
epidermis with strong localization to the cell membrane
(Figure 2A, see Figure S3 for antibody specificity). This
was also the case in the normal esophagus epithelium. In
contrast, tylotic skin (biopsied from individuals from the
UK family, n ¼ 2) showed a reduction in RHBDF2 in the
cell membrane (Figure 2B). Plasma-membrane staining
with an antibody against the desmosomal cadherin
proteins desmogleins 1 and 2 revealed that the membrane
integrity was maintained in the tylotic sections as seen in
the normal skin (Figure 2C and 2D).
RHBDF2 was also analyzed in cultured keratinocytes.
After gaining appropriate consent, we obtained biopsy
samples from affected (papular) skin frommale and female
tylosis patients (TYLK1 and TYLK2, respectively), breast
skin from a 31-year-old healthy female (K1), and leg skin
from a 45-year-old healthy female (K16). Primary keratino-
cytes were isolated and grown in the presence of a g-irradi-
ated 3T3 feeder layer.18 Cells were immortalized with
HPV16 (E6/E7) as described previously.19 All experiments
were carried out on cells that had been passaged between
10 and 40 times postimmortalization. Control cells were
immortalized in the same way and have been described
previously.20 Cells were cultured in DMEM:Ham’s F12
medium (Invitrogen Ltd, Paisley, UK) at a 3:1 ratio with
10% fetal calf serum (ICN Biomedicals, Costa Mesa, CA)
and were supplemented with 0.4 mg/ml hydrocortisone
(Sigma-Aldrich), 1010 M cholera toxin (Sigma-Aldrich, St
Louis, MO, USA), and 5 mg/ml insulin (Sigma-Aldrich) at
37C in 10% CO2. Cells were routinely cultured in media
containing 10 ng/ml recombinant EGF (AbD Serotec
Raleigh, NC, USA), which was omitted where indicated.
We determined cell numbers by using a CASY Model TT
cell counter (Roche Diagnostics, West Sussex, UK). Total
protein was extracted, resolved under reducing conditions
on a 4%–15% Mini-PROTEAN TGX precast gel (BioRad),
transferred to Hybond ECL (GE Healthcare), incubated
with the appropriate antibodies, and detected with the
ECL Advance Western Blotting Detection Kit (GE Health-
care Life Sciences, Buckinghamshire, UK) according to
the manufacturers’ directions. Immunoblotting of lysates
from immortalized tylotic keratinocytes confirmed a reduc-
tion of RHBDF2 compared to control keratinocytes
(Figure 2E).
Because EGFR activation can be regulated indirectly by
iRhoms, EGFR activity was investigated. Total EGFR levels
were lower in tylotic keratinocytes in control cells (Fig-
ure 3A; quantification shown in Figure S4). This could be10, 2012
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Figure 2. RHBDF2 Localization is Altered in
Tylotic Skin
Immunofluorescence staining of frozen sections
from normal skin (A) and tylotic skin (B).
RHBDF2 appears to localize predominantly to
the cell membrane in sections from normal
skin, whereas the localization is mostly cyto-
plasmic in skin sections from patients with
tylosis. Plasma-membrane staining with an anti-
body against the desmosomal cadherin proteins
desmogleins 1 and 2 is shown in normal skin
(C) and tylotic skin (D) and reveals that the local-
ization of at least one other plasma-membrane
protein remains the same in the tylotic-skin
sections as it is in the normal-skin sections. Scale
bars represent 20 mm.
(E) Immunoblotting of lysates from control kera-
tinocyte cell lines K1 and K16 and tylotic cell
lines TYLK1 and TYLK2 cultured in the presence
of exogenous EGF with anti-RHBDF2 shows
a reduction in RHBDF2 levels in tylotic keratino-
cytes. The use of anti-actin demonstrated equal
loading.consistent with postactivation EGFR downregulation,
which can occur via a number of mechanisms (reviewed
in Segatto et al., 2011).21 EGFR dysregulation is seen in
many tumor types, including those of the esophagous.22
In addition, when we cultured the tylotic keratinocytes
in the absence of exogenous EGF, we observed that
their behavior was quite different from that of control
keratinocytes (n ¼ 2, K1 and K16), which were cultured
in medium supplemented with EGF. The behavior of
tylotic keratinocytes suggests that exogenous EGF had
little effect on them. To investigate this further, we
measured the proliferation rates of normal and tylotic
keratinocytes with an assay of mitochondrial dehydroge-
nase activity (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxy-
methoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner
salt [MTS]) when they were cultured in the presence and
absence, respectively, of exogenous EGF. In contrast to
control keratinocytes, tylotic cells did not show any
increased proliferation when they were switched to an
EGF-containing medium, indicating that they were not
responsive to EGF (Figure 3B).
Because EGF signaling is strongly implicated in cell
adhesion and migration, we performed scratch assays to
imitate trauma and wounding in keratinocytes in order to
assess the effect of mutant RHBDF2 on these cellular
processes. Cells were seeded at equal density (3 3 105/well
in a24-well plate) and grown for 16–48hr inmedia contain-
ing EGF. We wounded the resulting confluent cultures by
scraping a 1 ml micro-Gilson pipette tip across the center
of the well to remove cells in a linear fashion, leaving
a width of 0.5–1.5 mm. Cultures were washed three timesThe American Journal of Humbefore they were incubated in media with
or without EGF as indicated. Media were
changed each day, and cells were photo-
graphed consecutively for 3 days or until
the wounds had closed. The wounded areaswere measured with Adobe Photoshop CS5 (Adobe). After
calibration, we calculated the migrated distances by sub-
tracting the area at each time point from the area immedi-
ately after we scraped the wells (time zero). Both tylotic
cell lines migrated much more quickly than the control
cell lines and did so in an exogenous EGF-independent
manner (Figures 3C and 3D). The migration of control ker-
atinocytes was greatly enhanced with EGF in the media
(Figure 3D) but was still less than that of tylotic cells.
To investigate RHBDF2 localization in tylotic and spo-
radic squamous esophageal tumors, we cut 3 mm for-
malin-fixed, paraffin-embedded wax blocks with a rotary
microtome (Thermo Fisher Scientific, Waltham, MA,
USA) and applied them to 3-aminopropyltrioxysilane-
coated slides. The sections were dried overnight at 37C.
The slides were de-waxed and dehydrated in two changes
of Xylene and Industrial Methylated Spirit (IMS) for
3 min each. Heat-mediated antigen retrieval was carried
out, and endogenous peroxidase was blocked with 0.3%
hydrogen peroxide for 10 min. Staining was carried out
with the RTU kit (Vector Laboratories Ltd., Peterborough,
UK) and two-component 3,30-diaminobenzidine (Launch
Diagnostics Ltd., Kent, UK). Light microscopy was carried
out with the Leica DM5000B epi-fluorescence microscope.
Squamous esophageal tumors from both tylotic (n ¼ 2)
and sporadic (n ¼ 4) cases also show cytoplasmic localiza-
tion of RHBDF2 (Figure 4).
The high risk of developing squamous cell esophageal
carcinoma in the tylosis-affected families indicates the
importance of the TOC-associated gene, RHBDF2, in the
molecular pathogenesis of this malignancy. Its importancean Genetics 90, 340–346, February 10, 2012 343
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Figure 3. Tylosis Cell Lines Show Increased Migration and Are Less Responsive to Exogenous EGF
(A) Immunoblotting of lysates from control cells K1 and K16 and tylotic cells TYLK1 and TYLK2 blotted with anti-phospho-EGFR and
anti-EGFR (total) shows a reduction in the levels of total EGFR in the lysates from tylotic cells. The use of anti-b-actin demonstrated equal
loading. Cells were grown in the absence of exogenous EGF.
(B) An MTS proliferation assay shows proliferation levels in two tylotic cell lines, TYLK1 and TYLK2, and two control cell lines, K1 and
K16, after a 72 hr culture in the presence and absence of exogenous EGF. The assay was carried out in quadruplicate (p ¼ 0.00035).
(C) Light-microscopy images of cells 2 days after we scraped them in the absence of exogenous EGF. The experiment was carried out in
triplicate, and a representative image is shown from each experiment for control cell lines K1 and K16 and for tylotic cell lines TYLK1 and
TYLK2.
(D) Quantification of migration of control cells and tylotic cells: (1) after 1 day in the presence of EGF (p ¼ 0.025, experiments in
duplicate, control cells n ¼ 2, tylosis cells n ¼ 1) and (2) after 3 days in the absence of EGF (p ¼ 2.13 3 106, experiments in triplicate,
n ¼ 2 in each case).is substantiated by findings of chromosomal deletions
around the TOC locus in region 17q25 in the sporadic
form of esophageal cancer23–26 as well as by our data
showing dysregulated RHBDF2 localization in sporadic
cases of TOC. It is of note that a similarly located minimal
region of deletion at 17q25 has been described in ovarian
cancer, and RHBDF2 was postulated as being the strongest
candidate for containing a causative mutation in this
region.27 Our functional data suggest that the altered
RHBDF2 represents a gain-of-function allele that results344 The American Journal of Human Genetics 90, 340–346, Februaryin sustained EGFR signaling within the cells; this sustained
EGFR signaling, in turn, leads to a hyperproliferative
phenotype. Our results support the hypothesis that tylosis
results from dysregulated wound repair that leads to
precancerous lesions in the esophagus and other nonkera-
tinized epithelium of the upper gastrointestinal tract.
In summary, we have identified RHBDF2missense muta-
tions as the underlying cause of a highly penetrant form of
inherited esophageal cancer. Furthermore, our preliminary
immunohistochemical data suggest that RHBDF2 might10, 2012
Figure 4. Squamous Esophageal Tumors Show Cytoplasmic
Localization of RHBDF2
Immunohistochemical staining of formalin-fixed, paraffin-
embedded sections from a control esophagus with esophagitis
(A), tylotic (B), and sporadic (C) squamous cell tumors. The local-
ization of RHBDF2 in both tumor types is strongly cytoplasmic
compared to the control tissue. Scale bars represent 20 mm.also be dysregulated in a similar manner in sporadic esoph-
ageal squamous cell carcinomas, in which case these
tumors might be resistant to treatment with EGFR inhibi-
tors. Therefore, developing chemotherapies targeted to
RHBDF2-regulated pathways could be more effective in
reducing the hyperproliferative and invasive aspects of
esophageal cancers. Characterizing the TOC-associated
gene will contribute to understanding the more common,
sporadically occurring esophageal cancer, a major cause of
mortality in both developing and developed countries.The AmericaSupplemental Data
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